Leerink Partners Thinks Privia Health Group’s Stock is Going to Recover

In a report issued on February 10, Whit Mayo from Leerink Partners reiterated a Buy rating on Privia Health Group (PRVAResearch Report), with a price target of $43.00. The company’s shares closed last Friday at $23.79, close to its 52-week low of $18.93.

According to, Mayo is a 4-star analyst with an average return of 8.0% and a 55.3% success rate. Mayo covers the Healthcare sector, focusing on stocks such as Airsculpt Technologies, Inc., Surgery Partners, and Universal Health.

Currently, the analyst consensus on Privia Health Group is a Strong Buy with an average price target of $41.33.

See today’s best-performing stocks on TipRanks >>

Based on Privia Health Group’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $252 million and GAAP net loss of $9.12 million. In comparison, last year the company earned revenue of $207 million and had a net profit of $16.69 million.

Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PRVA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.

Read More on PRVA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed